Research collaboration to investigate new treatments for AMD

Berlin, Germany-Jerini AG's U.S. subsidiary, Jerini Ophthalmic Inc., signed a research collaboration agreement with University College London (UCL) Institute of Ophthalmology to investigate the pathobiology of age-related macular degeneration (AMD).

Berlin, Germany-Jerini AG's U.S. subsidiary, Jerini Ophthalmic Inc., signed a research collaboration agreement with University College London (UCL) Institute of Ophthalmology to investigate the pathobiology of age-related macular degeneration (AMD).

Two of Jenrini Ophthalmic's leading drug candidates, JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of the component cascade will be tested.

The projects will collaborate with UCL's new Translational Vision Research Laboratory, headed by David T. Shima, PhD, recently appointed Rothes professor at UCL and chief scientific officer for Jenrini Ophthalmic.

"Our collaboration with David Shima and UCL gives Jerini Ophthalmic access to the best resources and expertise available in the field of ophthalmology," said Anthony P. Adamis, chief executive officer and president of Jerini Ophthalmic. "Working closely with the exceptional UCL research infrastructure will enable us to optimally develop and advance our ophthalmology drug candidates."